Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study of Novel Therapies for Recurrent/Progressive ATRT
NCT07447076Phase 2Recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2035
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, paxalisib in Atypical teratoid rhabdoid tumor (ATRT). Started Jun 2026; status: recruiting.
02
Drugs
gemcitabinepaxalisib
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT07447076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447076.